ebomi
Colour theme
Sign in
Insider · CIK 0001376960

Aryeh Jason

CIK 0001376960 Name as filed on the most recent filing

Filed as Aryeh Jason (95)

204 transaction lines · from 95 filings · filed 2007-06-01 to 2026-06-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

204 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,865, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,860, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,850, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,830, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,815, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,795, acquired Open Form 4 filing 0000886163-11-000031
2011-03-14 S, Open-market sale Nabi BiopharmaceuticalsNABI 2 lines 19,828, disposed Open Form 4 filing 0001455244-11-000008
2011-03-11 S, Open-market sale Nabi BiopharmaceuticalsNABI 3 lines 142,171, disposed Open Form 4 filing 0001491877-11-000007
2011-03-11 P, Open-market purchase Ligand Pharmaceuticals IncLGND 8 lines 39,355, acquired Open Form 4 filing 0000886163-11-000039
2011-03-10 P, Open-market purchase Ligand Pharmaceuticals IncLGND 3 lines 15,125, acquired Open Form 4 filing 0000886163-11-000027
2011-02-23 P, Open-market purchase Ligand Pharmaceuticals IncLGND 49,700, acquired Open Form 4 filing 0000886163-11-000019
2010-12-27 S, Open-market sale Nabi BiopharmaceuticalsNABI 86,634, disposed Open Form 4 filing 0001455244-10-000151
2010-12-15 S, Open-market sale Nabi BiopharmaceuticalsNABI 10,946, disposed Open Form 4 filing 0001455244-10-000149
2010-12-15 S, Open-market sale Nabi BiopharmaceuticalsNABI 10,946, disposed Open Form 4 filing 0001455244-10-000147
2010-12-08 S, Open-market sale Nabi BiopharmaceuticalsNABI 25,830, disposed Open Form 4 filing 0001455244-10-000145
2010-12-01 S, Open-market sale Nabi BiopharmaceuticalsNABI 37,051, disposed Open Form 4 filing 0001455244-10-000143
2010-11-22 S, Open-market sale Nabi BiopharmaceuticalsNABI 14,868, disposed Open Form 4 filing 0001455244-10-000141
2010-11-19 S, Open-market sale Nabi BiopharmaceuticalsNABI 2,431, disposed Open Form 4 filing 0001455244-10-000141
2010-11-18 S, Open-market sale Nabi BiopharmaceuticalsNABI 25,676, disposed Open Form 4 filing 0001455244-10-000141
2010-11-11 S, Open-market sale Nabi BiopharmaceuticalsNABI 25,970, disposed Open Form 4 filing 0001455244-10-000139
2010-11-10 S, Open-market sale Nabi BiopharmaceuticalsNABI 60,402, disposed Open Form 4 filing 0001455244-10-000137
2010-11-09 S, Open-market sale Nabi BiopharmaceuticalsNABI 33,677, disposed Open Form 4 filing 0001455244-10-000137
2010-10-20 S, Open-market sale Nabi BiopharmaceuticalsNABI 42,851, disposed Open Form 4 filing 0001455244-10-000135
2010-10-18 S, Open-market sale Nabi BiopharmaceuticalsNABI 60,100, disposed Open Form 4 filing 0001455244-10-000135
2010-10-11 S, Open-market sale Nabi BiopharmaceuticalsNABI 22,110, disposed Open Form 4 filing 0001455244-10-000132
2010-06-11 S, Open-market sale Nabi BiopharmaceuticalsNABI 3,446, disposed Open Form 4 filing 0001455244-10-000128
2010-06-11 S, Open-market sale Nabi BiopharmaceuticalsNABI 12,324, disposed Open Form 4 filing 0001455244-10-000116
2010-06-03 S, Open-market sale Nabi BiopharmaceuticalsNABI 1,499, disposed Open Form 4 filing 0001435420-10-000002
2010-06-01 P, Open-market purchase Ligand Pharmaceuticals IncLGND 7,400, acquired Open Form 4 filing 0000886163-10-000053
2010-05-25 P, Open-market purchase Ligand Pharmaceuticals IncLGND 10,750, acquired Open Form 4 filing 0000886163-10-000045
2010-05-24 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,064, acquired Open Form 4 filing 0000886163-10-000045
2010-05-20 P, Open-market purchase Ligand Pharmaceuticals IncLGND 874, acquired Open Form 4 filing 0000886163-10-000043
2010-03-24 S, Open-market sale Nabi BiopharmaceuticalsNABI 1,460, disposed Open Form 4 filing 0001455244-10-000085
2010-03-23 S, Open-market sale Nabi BiopharmaceuticalsNABI 404,833, disposed Open Form 4 filing 0001455244-10-000085
2010-03-22 S, Open-market sale Nabi BiopharmaceuticalsNABI 177,902, disposed Open Form 4 filing 0001455244-10-000083
2010-03-19 S, Open-market sale Nabi BiopharmaceuticalsNABI 46,722, disposed Open Form 4 filing 0001455244-10-000081
2010-03-18 S, Open-market sale Nabi BiopharmaceuticalsNABI 2 lines 39,225, disposed Open Form 4 filing 0001455244-10-000077

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 88
  • Open-market sale 116
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Aryeh Jason, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001376960

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.